Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans—A Diagnostic Prediction Model
Open Access
- 15 March 2023
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 13 (3) , 532
Abstract
Impaired glycosaminoglycans (GAGs) catabolism may lead to a cluster of rare metabolic and genetic disorders called mucopolysaccharidoses (MPSs). Each subtype is caused by the deficiency of one of the lysosomal hydrolases normally degrading GAGs. Affected tissues accumulate undegraded GAGs in cell lysosomes and in the extracellular matrix, thus leading to the MPS complex clinical phenotype. Although each MPS may present with recognizable signs and symptoms, these may often overlap between subtypes, rendering the diagnosis difficult and delayed. Here, we performed an exploratory analysis to develop a model that predicts MPS subtypes based on UHPLC-MS/MS measurement of a urine free GAG profile (or GAGome). We analyzed the GAGome of 78 subjects (38 MPS, 37 healthy and 3 with other MPS symptom-overlapping disorders) using a standardized kit in a central-blinded laboratory. We observed several MPS subtype-specific GAGome changes. We developed a multivariable penalized Lasso logistic regression model that attained 91.2% balanced accuracy to distinguish MPS type II vs. III vs. any other subtype vs. not MPS, with sensitivity and specificity ranging from 73.3% to 91.7% and from 98.4% to 100%, depending on the predicted subtype. In conclusion, the urine GAGome was revealed to be useful in accurately discriminating the different MPS subtypes with a single UHPLC-MS/MS run and could serve as a reliable diagnostic test for a more rapid MPS biochemical diagnosis.Keywords
Funding Information
- Elypta AB
This publication has 18 references indexed in Scilit:
- Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must knowItalian Journal of Pediatrics, 2018
- Glycosaminoglycan fragments as a measure of disease burden in the mucopolysaccharidosis type I mouseMolecular Genetics and Metabolism, 2018
- Sulfation of Glycosaminoglycans and Its Implications in Human Health and DisordersAnnual Review of Biomedical Engineering, 2017
- Glycosaminoglycans detection methods: Applications of mass spectrometryMolecular Genetics and Metabolism, 2017
- Proteoglycan form and function: A comprehensive nomenclature of proteoglycansMatrix Biology, 2015
- Urinary Glycosaminoglycan Electrophoresis With Optimized Keratan Sulfate Separation Using Peltier System for the Screening of MucopolysaccharidosesJournal of Inborn Errors of Metabolism and Screening, 2015
- Analysis of glycosaminoglycan-derived, precolumn, 2-aminoacridone–labeled disaccharides with LC-fluorescence and LC-MS detectionNature Protocols, 2014
- Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses - an evaluationAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2007
- Pitfalls of screening for mucopolysaccharidoses by the dimethylmethylene blue testClinical Chemistry, 1993
- Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion.Clinical Chemistry, 1989